Ask AI
ProCE Banner Activity

DLL3 Targeting in Extrapulmonary Neuroendocrine Carcinomas: A New Approach for an Unmet Clinical Need

Clinical Thought

Read this commentary on the latest data for DLL3-targeted agents and how they could fill a gap in the EP-NEC treatment paradigm.

Released: November 17, 2025

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by an educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.

Boehringer Ingelheim Pharmaceuticals, Inc.

Faculty Disclosure

Primary Author

Daniel Morgensztern, MD: consultant/advisor/speaker: AbbVie, Bayer, Bristol Myers Squibb, Johnson & Johnson/Janssen, Natera, Tubulis; researcher (paid to institution): AbbVie, AstraZeneca, Bristol Myers Squibb, Celgene, EpicentRx, Merck, Pfizer.

Jonathan Strosberg, MD: consultant/advisor/speaker: Boehringer Ingelheim, Curium, Exelixis.